Figure 2. DOR in patients with bTMB-H treated with (A) nivolumab+ipilimumab or (B) nivolumab monotherapy, and best change from baseline in target lesion size in patients with bTMB-H treated with (C) nivolumab+ipilimumab or (D) nivolumab monotherapy. Horizontal bars in A, B represent progression-free survival. Asterisks in C, D represent responders. Dashed horizontal reference lines in C, D indicate a 30% reduction, consistent with a RECIST V.1.1 response. BICR, blinded independent central review; bTMB-H, high blood tumor mutational burden; CR, complete response; DOR, duration of response; PR, partial response; tTMB-H, high tissue tumor mutational burden.